Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Tango Therapeutics to go public in $353 million SPAC deal

By Anissa Gardizy — Boston GlobeApril 14, 2021

Reprints
Human Colon Cancer Cells
Human colon cancer cells. NCI Center for Cancer Research

Cambridge biotech Tango Therapeutics is going public through a $353 million deal with a special purpose acquisition company, the precision cancer medicine firm announced on Wednesday.

The SPAC, called BCTG Acquisition Corp., is backed by Boxer Capital, one of the biotech’s investors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Anissa Gardizy — Boston Globe

Tags

Drug used to halt puberty in children may cause…
Drug used to halt puberty in children may cause lasting health problems
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Why you get paid to donate plasma but not…
Why you get paid to donate plasma but not blood
Patient groups balk at former AstraZeneca official negotiating U.K.-India…
Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal
Altimmune’s obesity drug fails to stand out from blockbuster…
Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data
Pharmalittle: FDA official wants to use accelerated approval for…
Pharmalittle: FDA official wants to use accelerated approval for gene therapies; pharma asks Biden for tax…

Recommended Stories